Solomon: Immunai's database spans over 100,000 patients across 500 diseases
Noam Solomon · HIBT Lab! Immunai: Noam Solomon · Dec 22, 2022 · at 17:39
Noam Solomon, CEO and co-founder of Immunai, explains how the company builds its MICA database by sequencing biological samples received from academic and biopharma partners.
0:00 / 0:19exact quote · 19.7s
720p mp4 · rendered on demand · StarZero watermark
“It is the largest of its kind database of the immune system with a single cell resolution. So today we have a database that spans over 100,000 patients, over 500 different disease indications, thousands of studies, and we're trying to put as much clinical context and clinical metadata into the patients.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Noam Solomon
Solomon: Immune system mapping enables data-driven drug discovery
“Having a map of the human immune system will enable researchers to apply data mining tools to come up with novel ways to develop and discover therapeutics.”
Solomon predicts immune profiling will enable preventative healthcare within 15 years
“The vision that I have and the hope that I have is that maybe in 15 years, We'll be able to use our new profile and capabilities to help people remain healthy.”
Solomon: Bridging animal testing to humans is biotech's biggest challenge
“Understanding how to bridge the gap between the human immune response and the way that drugs are being tested in animal models. Is, I believe, the biggest challenge that the biopharma and biotechnology industry should face and will face in the coming, ah, deca…”
Solomon: Immunai's platform successfully identifies superior clinical drug combinations
“We were able to show quite definitively that our platform can identify the preferred combination arm that will demonstrate a superior immune response. So it happened already.”